Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk AS    NOVO B   DK0060534915


Real-time Quote. Real-time CHI-X - 06/25 11:30:00 am
338.5 DKK   +1.36%
08:53aNOVO NORDISK AS : The underlying trend is to the upside
06/24NOVO NORDISK : Disclosure of transaction data
06/24NOVO NORDISK A/S : – Share repurchase programme
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novo Nordisk : Trial shows cardiovascular safety with Novo Nordisks diabetes drug

share with twitter share with LinkedIn share with facebook
share via e-mail
06/13/2019 | 06:36am EDT

Novo Nordisk has reported that its oral semaglutide medicine showed non-inferiority compared to placebo in major adverse cardiovascular events (MACE) during the PIONEER 6 clinical trial in type 2 diabetes patients.

The trials primary endpoint was the MACE composite outcome of the first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke.

PIONEER 6 met the endpoint with a hazard ratio of 0.79 in favour of semaglutide compared to placebo.

The data is an aggregation of 137 first major adverse cardiovascular events and a median follow-up of 16 months.

Oral semaglutide is an investigational glucagon-like peptide-1 (GLP-1) analogue formulated as a pill.

The randomised, double-blinded, placebo-controlled, event-driven, pre-approval cardiovascular outcomes trial compared the cardiovascular safety of the therapeutic to placebo when added to standard of care. It recruited a total of 3,183 patients at high risk of cardiovascular events.

According to the findings, the MACE was driven by its individual components.

Cardiovascular death events were 15 with oral semaglutide compared to 30 with placebo, while non-fatal stroke events were 12 versus 16.

However, the number of non-fatal myocardial infarctions with the therapeutic was not significantly different to placebo, with the numbers being recorded at 37 and 31, respectively.

In addition, the oral semaglutide group showed significantly lower all-cause deaths compared to patients on placebo.

During the trial, the safety profile of Novo Nordisks drug was consistent with that of the GLP-1 receptor agonist class and similar to subcutaneous semaglutide.

Novo Nordisk executive vice-president and chief science officer Mads Krogsgaard Thomsen said: The results of PIONEER 6 further strengthen the overall clinical evidence for oral semaglutide, building upon the strong clinical data reported throughout the PIONEER clinical trial programme.

We are excited about the potential of oral semaglutide to become the first and only oral GLP-1 treatment for people with type 2 diabetes.

The PIONEER clinical development programme involved 9,543 type 2 diabetes patients in ten trials.

(c) 2003-2019 SudanTribune - All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVO NORDISK AS
04:56aNOVO NORDISK : EMA clears Novo Nordisks long-acting haemophilia A drug
06/24NOVO NORDISK : Disclosure of transaction data
06/24NOVO NORDISK A/S : – Share repurchase programme
06/22NOVO NORDISK : Esperoct (turoctocog alfa pegol, N8-GP) approved in the EU
06/21NOVO NORDISK : Esperoct approved in the EU
06/20Esperoct® (turoctocog alfa pegol, N8-GP) approved in the EU
06/20NOVO NORDISK : FDA approves Novo Nordisks type 2 diabetes drug Victoza
06/17NOVO NORDISK : FDA Approves Novo Nordisk Treatment for Type 2 Diabetes in Pediat..
06/14Morphic Holding Sets IPO at 5 Million Shares; Sees Pricing at $14-$16 Apiece
06/13Health Care Down on Cyclical Bias -- Health Care Roundup
More news
Financials (DKK)
Sales 2019 120 B
EBIT 2019 52 007 M
Net income 2019 38 788 M
Finance 2019 13 330 M
Yield 2019 2,49%
P/E ratio 2019 20,39
P/E ratio 2020 17,88
EV / Sales 2019 5,08x
EV / Sales 2020 4,76x
Capitalization 622 B
Duration : Period :
Novo Nordisk AS Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK AS
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 28
Average target price 343  DKK
Spread / Average Target 2,8%
EPS Revisions
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK AS12.10%91 011
JOHNSON & JOHNSON10.10%348 981
PFIZER0.05%233 072
ROCHE HOLDING LTD.13.50%227 848
NOVARTIS21.44%220 893
MERCK AND COMPANY11.91%206 641